CEA cell adhesion molecule pseudogene 2Genealiases: CEACAM23P · CGM9
Q-omics provides the consensus-scored CEACAMP2 profile across patient tissues and cancer cell-line models. CEACAMP2 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, CEACAMP2 is differentially expressed in 2, with the highest sampling consensus in ESCA. Additionally, CEACAMP2 RNA expression shows 6,354 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight THCA, ESCA, and LAML as cancer lineages where CEACAMP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CEACAMP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CEACAMP2 survival associations across molecular data types. CEACAMP2 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CEACAMP2 RNA expression–survival associations across cancer types. High CEACAMP2 expression shows unfavorable associations in THCA, MESO, COAD, KICH and ACC, but favorable associations in CESC. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify THCA as the clearest survival context for CEACAMP2 RNA expression.
This table summarizes CEACAMP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for CEACAMP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CEACAMP2 shows lower tumor expression in BRCA and higher tumor expression in ESCA. The ESCA box plot shows higher CEACAMP2 RNA expression in tumor versus normal tissue (log2 FC = +0.130, t-test p = .022).
This table shows molecular features associated with CEACAMP2 in patient tissues and cancer cell lines. In patient samples, CEACAMP2 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
